Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Treatment Resistant Depression

In brief

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Key facts

Study ID
NCT05624268
Run by
COMPASS Pathways
People needed
255
Starts
2023-01-19
Expected to finish
2026-04-01
Last updated by the study team
2025-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.